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component of the innate immune system specialized to kill host
cells that have become transformed or virally infected [1]. KIR are
diverse in terms of the number, type, and combination of genes
present in individuals, and display extensive polymorphism at the
nucleotide level. The ligands for NK receptors include the poly-
morphic human leukocyte antigen (HLA) class I cell surface mol-
ecules. Recent evidence suggests that interactions between an in-
dividual’s KIR molecular proﬁle and HLA class I ligands may play
an important role in stem cell transplant outcome; NK activation
may be of beneﬁt in hematopoietic transplants as donor NK cells
in a KIR/HLA mismatched transplant have shown the ability to
attack host leukemias and reduce graft versus host disease and graft
rejection [2,3,5]. Thus assessment of KIR genotypes may become
part of the donor selection process. As part of a larger study to
analyze the role of donor and recipient KIR and HLA ligand
proﬁles in stem cell transplantation, we are developing a novel,
high-throughput single nucleotide polymorphism (SNP)-based
KIR genotyping methodology. In this assay, the masses generated
in a SNP-based primer extension reaction are analyzed on a ma-
trix-assisted laser desorption/ionization time-of-ﬂight mass spec-
trometer (MALDI-TOF). The method uses 384-well microarray
chips, and is both highly accurate and rapid [4]. We present data
using this novel typing method to demonstrate that the method is
capable of accurately deﬁning KIR genotypes in a panel of 100
donor recipient pairs from the NMDP. We are collaborating with
the NMDP on an analysis of the KIR/HLA proﬁles of this panel
and their relationship to hematopoietic transplant outcomes.
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EVALUATION OF UNRELATED DONOR SEARCH STRATEGY PROFICIEN-
CIES
Davis, J.W., Buck, K., Dorr, L., Kempenich, J., Beduhn, E., Maus, T.,
Setterholm, M., Chitphakdithai, P. National Marrow Donor Program,
Minneapolis, MN.
A study completed by the National Marrow Donor Program
(NMDP) evaluated search strategy proﬁciencies of U.S. transplant
centers in selecting matched unrelated donors (MUD). The three
objectives were: 1) to assess the quality of transplant center search
practices, 2) to evaluate effectiveness of NMDP services and 3) to
identify areas where further education is needed. Within the one
year study, the ﬁrst 5 new MUD searches were evaluated for each
transplant center. For centers with lower transplant activity, all
MUD searches were evaluated (15% had 4 searches). Search
indicators scored were: 1) patient HLA typing—loci and level of
resolution, 2) search strategy and 3) number of donors selected.
Scores were averaged and centers were placed into prospectively
determined groups. Center speciﬁc factors in the statistical evalu-
ation were: 1) use of NMDP HLA expert consultations, 2) receipt
of preliminary search reviews, 3) having Certiﬁed Hematopoietic
Transplant Coordinator (CHTC) staff, and 4) volume of unrelated
donor transplants per year. The study included 484 MUD searches
for 106 transplant centers. The cumulative scores separated
centers into three proﬁciency categories of high (56% of the
centers), medium (29%) and low (15%). Multivariate logistic
regression was performed to control for bias. Since the response
variable “proﬁciency category” is ordinal, a proportional odds
model was used, with the probability of having higher ranking
being modeled. After adjusting for other factors, expert HLA
consultations (P  .007) and CHTC (P  .03) signiﬁcantly
affected the proﬁciency ranking (Table 1). Centers with at least
one CHTC staff or centers using HLA expert consultations
tended to have higher rankings. Unrelated transplant volume
and receipt of NMDP preliminary search reviews did not sig-
niﬁcantly affect the performance ratings (Table 1). The majority
of the transplant centers scored in the highest category demon-
strating optimal practices. The transplant centers in the lowest
category tended to select too few donors and use less than
optimal resolution for recipient HLA typing, indicating a need
for targeted education in these areas. Two NMDP programs,
Certiﬁed Hematopoietic Transplant Coordinator and HLA
search consultation, were signiﬁcantly associated with optimal
search practices.
Table 1. Logistic Regression Result for TC Proﬁciency Rankings
Factor
Odds
Ratio
95%
CI
P
Value
Favorable
Characteristic
Center volume Not significant
Low 1  
Medium and high 1.85 (0.82, 4.15) .10
HLA consultant used? Used HLA consultant
No 1  
Yes 3.96 (1.45, 10.86) .007
CHTC staff Had CHTC staff
No 1  
Yes 2.46 (1.08, 5.57) .03
Preliminary reviews Not significant
No 1  
Yes 1.47 (0.67, 3.26) .30
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Conventional allogeneic hematopoietic cell transplantation
(HCT) is an effective treatment for patients with acute myeloge-
nous leukemia (AML), but its use is restricted to younger individ-
uals in good medical condition. The use of low-dose irradiation
based preparative regimens has allowed the extension of allograft-
ing to older and medically inﬁrm patients. The present study
included 122 patients, 117 of whom were ineligible for conven-
tional HCT. Their disease stages ranged from complete remission
(CR1) to resistant AML. Patients were conditioned with 200 cGy
TBI on day 0 with or without preceding ﬂudarabine (30 mg/m2/
day from days 4 to 2), and given postgrafting cyclosporine at
6.25 mg/kg twice daily from day 3 and mycophenolate mofetil at
15 mg/kg twice daily from day 0. Human leukocyte antigen (HLA)
matched related donors were used in 58 and HLA matched/par-
tially mismatched unrelated donors in 64 patients. Among the
121 evaluable patients, 117 (96.7%) had durable hematopoietic
engraftment. Cumulative incidences of acute graft-versus-host
disease (GvHD) grades II-IV at 6 months were 33% after
related and 42% after unrelated HCT, respectively. With a
median follow up of 17 months (range 4-57), 58 patients were
alive, 53 of whom were in complete remission. Cumulative
non-relapse mortalities were 12% and 27%, and cumulative
mortalities from disease progression were 46% and 34% at 2
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years for related and unrelated recipients, respectively. Two
year overall survival was 42% and disease-free survival was 36%,
with disease stages and cytogenetic risks being major determi-
nants for outcome. Patients transplanted in CR1 had 2-year
overall survivals of 40% after related and 57% after unrelated
HCT. We conclude that HCT from related and unrelated
donors after low-dose TBI is a promising treatment for elderly
patients and medically inﬁrm younger patients with AML not
eligible for conventional HCT.
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FEWER EARLY BACTERIAL AND VIRAL INFECTIONS FOLLOWING NON-
MYELOABLATIVE VS. MYELOABLATIVE CONDITIONING FOR ALLO-
TRANSPLANTATION
Bachanova, V., Brunstein, C., Burns, L.J., Miller, J.S., Tan, Y.,
van Burik, J., Weisdorf, D., Tomblyn, M. University of Minnesota, Divi-
sion of Hematology, Oncology, and Transplantation, Minneapolis, MN.
To examine the incidence and timing of infectious complications,
we reviewed 141 consecutive lymphoma patients receiving allogeneic
hematopoietic stem cell transplantation using either myeloablative
(MA) (n  65) or non-myeloablative (NMA) (n  76) conditioning.
The NMA cohort was older (48.4 vs 41.4 years, P .01), more often
given unrelated umbilical cord blood as a stem cell source (43% vs
9%, P .01), had comparable CMV seropositivity (39% vs 49%) and
39% had received a prior autologous transplant. All patients received
antimicrobial prophylaxis including an extended spectrum ﬂuoroquin-
olone, ﬂuconazole, and acyclovir in addition to weekly CMV surveil-
lance. The time to initial infection was determined for each patient to
analyze potential differences in types and time to onset of infection
between the cohorts. For this, patients were evaluated once in each of
three microbial categories bacterial, viral, and fungal (Table 1). Fatal
infections were uncommon and the incidence was similar in the MA
and NMA cohorts [MA: 12 (18%); NMA: 12 (16%)]. In the peri-
transplant period (day 0-30), the MA cohort had 2.2-fold greater
primary bacterial infections, but the risks of initial bacterial infection
were similar in the early (day 31-100) and late (day 101-365) post
transplant periods. Viral infections were twice as frequent in the MA
cohort during the peritransplant period though similar from day
30-100. Beyond day 100, the MA cohort again had 2-fold greater
primary viral infections. Fungal infections developed in approximately
10% of patients in both cohorts and the risks were similar during all
three time periods. These data demonstrate a signiﬁcantly greater
incidence of bacterial and viral peri-transplant infections using MA
conditioning though infectious mortality was similar using either
conditioning. Quicker engraftment and shorter periods of neutrope-
nia may explain in part the reduced incidence of initial peri-transplant
bacterial infections in the NMA cohort, but the pathophysiology
underlying the later infectious risks is uncertain. Immune reconstitu-
tion is delayed after both MA and NMA conditioning but protection
against infection appears similar using either treatment approach.
Future studies to correlate immune reconstitution with infections are
required to identify patients at greatest risk of later infections and to
design new strategies for their prevention.
Table 1. Incidence of Infections
Myeloablative Non-myeloablative P-Value
Bacterial
Day 0–30 49% (36–62) 22% (13–32) <.01
Day 31–100 47% (28–66) 48% (35–62) NS
Day 101–365 23% (0–45) 11% (0–22) NS
Viral
Day 0–30 18% (9–28) 9% (3–16) .08
Day 31–100 31% (17–45) 44% (32–56) NS
Day 101–365 44% (25–64) 21% (7–35) .05
Fungal
Day 0–30 12% (4–21) 9% (3–16) NS
Day 31–100 12% (3–21) 13% (5–22) NS
Day 101–365 10% (1–20) 17% (7–28) NS
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We reviewed data on women who received allogeneic hema-
topoietic cell transplantation (HCT) for metastatic breast can-
cer at 16 centers participating in the CIBMTR and the EBMT
between 1992 and 2000. Probabilities of transplant-related mor-
tality (TRM), graft-vs-host disease (GVHD), disease relapse or
progression, progression-free survival (PFS), and overall sur-
vival were determined. Seventy-ﬁve patients were identiﬁed;
median age at transplantation was 41 years (range, 25-60).
Median follow-up time for survivors was 25 months (range,
3-64). Thirty-nine patients (52%) received myeloablative con-
ditioning regimens and 36 (48%) received reduced-intensity
conditioning (RIC) regimens. Nine of the RIC patients were
treated with a planned tandem autologous-allogeneic approach.
Patient characteristics were similar between the two groups
except that more patients in the RIC group (72%) had poor
pretransplant performance status than in the myeloablative
group (28%). More patients in the myeloablative group devel-
oped acute GVHD (44% vs 34% at 100 days), chronic GVHD
(36% vs. 8% at one year) and TRM (29% vs 7% at 100 days)
compared to RIC. Overall response rates (complete or partial
response) were 31% in the myeloablative group and 29% in the
RIC group. Eleven of 42 patients (26%) who underwent im-
mune manipulation (withdrawal of immunosuppression and/or
donor lymphocyte infusion) after transplantation had disease
control (complete, partial, minor, or stable response), providing
evidence of a graft-vs-tumor (GVT) effect. Overall survival at 2
yrs was 24% (15-35%) for all patients. PFS at 1 year was 23%
for myeloablative patients and 8% for RIC (excludes planned
tandem) patients. Development of acute GVHD after an RIC
regimen compared to no GVHD reduced the risk of relapse or
progression (RR 3.05, P  .03) in multivariate analysis, consis-
tent with a GVT effect, but this did not affect PFS. These
ﬁndings support development of innovative allotransplantation
approaches to exploit GVT effects for disease control while
minimizing TRM. Planned tandem autologous-allogeneic RIC
HCT, where probabilities of TRM and PFS at 2 years were 11%
and 44% respectively for a small number of patients in these
data, may represent such an alternative approach.
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The Australasian Bone Marrow Transplant Recipient Registry
(ABMTRR) has been recording activity and outcome data for
haemopoietic stem cell transplants in Australia since 1992 and New
Zealand since 1998. Between 1992 and 2004 there were 50 hae-
mopoietic stem cell transplants for chronic myeloﬁbrosis in Aus-
tralia and 1 in New Zealand. Of these, 46 were allogeneic, 3
syngeneic and 2 autologous; 35 were male and 16 were female. The
median age at transplant was 48 with a range of 16 to 71. The
annual number of transplants for this indication is small but in-
creasing. In the ﬁve years 2000 to 2004, there were 33 transplants
for this indication compared to 14 in 1995-1999. Of the donors for
allogeneic transplants, 33 were HLA-identical siblings, 3 were
siblings or other relatives with 1 HLA mismatch and 10 were
unrelated volunteers. Within the allogeneic transplants performed
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